OpenBilldrug price receipt

NADAC week of 2026-10-14

NEVIRAPINE ER 400 MG TABLET

For 30 tablets

Pharmacies pay

$47.16 filed

30 × $1.5719 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare

We don’t know yet

No Medicare reference price. Part D: The Part D file flags this drug’s average spending per dosage unit as an outlier, so OpenBill does not use it as a reference price. Part B: This NDC is not in the current quarter’s Medicare Part B NDC-HCPCS crosswalk, so it has no Part B payment limit.


The spread

We don’t know yet

There is no Medicare figure to compare with, so there is no spread.

Cost-plus estimate

$59.23 estimated

$47.16 + $7.07 (15%) + $5.00 fee per fill = $59.23

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

NEVIRAPINE ER 400 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as nevirapine.

FDA gives its dosage form as tablet, extended release and its route as oral.

Its labelers, the companies named on the label, are Mylan Pharmaceuticals Inc. and Macleods Pharmaceuticals Limited.

FDA’s Established Pharmacologic Class for it is Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $47.16 for 30 tablets (30 × $1.5719 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

All 2 NDCs

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name nevirapine with NEVIRAPINE ER 400 MG TABLET.

ProductPharmacies pay per unitMedicare per unit
NEVIRAPINE 200 MG TABLET
generic · tablet
$0.14722 per EA filed
eff. 2026-09-23
$0.53231 per EA filed
Part D 2024 average
NEVIRAPINE ER 400 MG TABLET this page
generic · tablet, extended release
$1.5719 per EA filed
eff. 2026-09-23
We don’t know yet

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $1.5719 per EA filed.

Of the 13 other products in FDA’s Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class priced per EA, 10 have a higher middle NADAC price and 3 a lower one. The one in the middle is EDURANT 25 MG TABLET, at $48.04095 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

We don’t know yet; the card above says why.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.